BNP Paribas Financial Markets’s 4D Molecular Therapeutics FDMT Stock Holding History

BNP Paribas Financial Markets’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$109K	Sell	8,196 -5,087	-38%	-$49.6K	﹤0.01%	4500
2026 Q1	$124K	Buy	13,283 +7,285	+121%	+$63.4K	﹤0.01%	4268
2025 Q4	$45K	Sell	5,998 -83,626	-93%	-$848K	﹤0.01%	4730
2025 Q3	$779K	Buy	89,624 +25,710	+40%	+$154K	﹤0.01%	3299
2025 Q2	$237K	Buy	63,914 +35,948	+129%	+$126K	﹤0.01%	3714
2025 Q1	$90.3K	Sell	27,966 -67,458	-71%	-$318K	﹤0.01%	4072
2024 Q4	$532K	Buy	+95,424	New	+$749K	﹤0.01%	3260

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

BNP Paribas Financial Markets's FDMT Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its 4D Molecular Therapeutics (FDMT) stake by 38% in Q2 2026, selling an estimated $49.6K and leaving 8,196 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #4500.

BNP Paribas Financial Markets first reported a position in FDMT in Q4 2024 and has held it in 7 quarters since. The position peaked at $779K in Q3 2025. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

BNP Paribas Financial Markets held 8,196 shares of 4D Molecular Therapeutics worth $109K as of Q2 2026.
BNP Paribas Financial Markets sold 5,087 4D Molecular Therapeutics shares in Q2 2026, an estimated $49.6K.
4D Molecular Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4500 holding.
BNP Paribas Financial Markets first reported a position in 4D Molecular Therapeutics in Q4 2024 and has held it in 7 quarters since.
BNP Paribas Financial Markets's 4D Molecular Therapeutics position peaked at $779K in Q3 2025.
157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.